Mon, November 27, 2023
Fri, November 24, 2023
Wed, November 22, 2023
Tue, November 21, 2023
Mon, November 20, 2023
Sun, November 19, 2023
Fri, November 17, 2023
Thu, November 16, 2023

Andreas Argyrides Initiated (SRPT) at Buy and Held Target at $224 on, Nov 21st, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. buy-and-held-target-at-224-on-nov-21st-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Andreas Argyrides of Wedbush, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $224 on, Nov 21st, 2023.

Andreas has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 1 agrees with Andreas's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $80 on, Thursday, November 2nd, 2023


These are the ratings of the 5 analyists that currently disagree with Andreas


  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $141 on, Thursday, November 2nd, 2023
  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $93 on, Thursday, November 2nd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
  • Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Tuesday, September 26th, 2023

Publication Contributing Sources